Novaliq Gmbh

Dermaliq Therapeutics, Inc.

Frank Löscher

Ralf Grillenberger

Hartmut Voss

Markus Beier

Dieter Scherer

Kirsten Eickhoff

Bernhard Günther

Sonja Krösser

Chiara Silvana Leo

Johan Engblom

Diana Strehl

Jörg Haisser

Thomas Schlüter

Alice Meides

Eike Hoppmann

Philip Kemp

Daniela Willen

Jörg Martin Mauden

Anja Sticher

Emanuele Franzini

Michael Coors

Sybille Burkhardt

Plamen Ivanov Bichovski

Salvatore Nicoletti

Philipp Steven

Veronika LÖSSL

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w/v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Ophthalmic composition for treatment of dry eye disease

The invention provides pharmaceutical compositions comprising cyclosporine dissolved in a semifluorinated alkane for use in the treatment of uveitis.

Ophthalmic composition for the treatment of uveitis

The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein the composition comprises tafluprost and a semifluorinated alkane.

Ophthalmic compositions comprising tafluprost for the treatment of glaucoma

The present invention relates to compositions comprising molecular iodine and a vehicle comprising a semifluorinated alkane. The compositions of the invention may be used to treat or prevent diseases or conditions caused by, or associated with microorganisms.

Iodine compositions

The present invention is directed to compositions comprising semifluorinated compounds and their use as medicaments for topical administration to the eye.

Semifluorinated compounds and their compositions

The present disclosure is in the field of ointments which can be useful for the treatment of diseases or conditions associated with lipid barrier damage of the skin. The ointment comprises a semifluorinated alkane and a solid thickening agent, e.g., a wax, a triglyceride, cetyl alcohol, cetyl palmitate, or tetradecanol.

Lipid barrier repair

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.

Opthalmic compositions comprising F6H8

The invention provides a pharmaceutical composition for use in the prevention or therapy of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith, wherein&#x2014;the composition comprises latanoprost and a liquid vehicle comprising a semifluorinated alkane; and&#x2014;the composition is administered to the eye of a subject; and&#x2014;the amount of latanoprost administered in a single dose per eye is in the range of from about 0.5 to 1.4 &#x3bc;g.

Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases

The present invention provides a pharmaceutical composition comprising 1-perfluorohexyl-octane (F6H8) for use in the therapy, treatment, prevention or amelioration of anterior or posterior blepharitis, preferably posterior blepharitis or symptoms associated therewith. Furthermore, the present invention provides a pharmaceutical kit for the therapy of anterior or posterior blepharitis or symptoms associated therewith.

Pharmaceutical compositions for use in the therapy of blepharitis

The present invention relates to pharmaceutical compositions comprising the selective beta 1 (B1)-receptor blocker nebivolol and/or a pharmaceutically acceptable salt thereof and a liquid vehicle comprising a semifluorinated alkane. The pharmaceutical composition of the present invention is useful for topical administration, for example ophthalmic topical administration and for use in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.

Pharmaceutical compositions comprising nebivolol

The present disclosure relates to topical sunscreen formulations comprising a semifluorinated alkane and a metal oxide selected from titanium dioxide, zinc oxide or mixtures thereof.

Topical sunscreen formulation

The present invention relates to compositions in the form of a clear solution comprising ciclosporin with low residual water content and 1-perfluorobutyl-pentane. The compositions may be used for topical administration to the eye.

Ophthalmic compositions comprising ciclosporin

The present invention is directed to certain semifluorinated compounds and to compositions comprising such compounds. The invention further provides the use of the compounds and of the compositions as medicaments for topical administration to the eye.

Growing community of inventors

Schriesheim, Germany

Frank Löscher